Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative Mar 26, 2026 11:30 AM Eastern Daylight Time Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative Share Bayer challenges industry to redefine canola innovation and reframe canola's future around real, lasting systems. CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science Canada launches Advancing Better Canola (ABCs), an industry-wide initiative to challenge and r ...

A more radical split of the drugs and crop-science businesses in Bayer, a pharmaceutical giant, would create the pure plays that investors favour https://t.co/iolnj0mm4f ...

CORPORATE OVERVIEW Bayer AG March 2026 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. 2 /// Bayer AG /// Corporate Overview /// March 2026 Global Leader in Health & Nutrition: Uniquely Positioned to Meet Basic Needs of Humankind Crop Science Pharmaceuticals Various known and unknown risks, uncertainties and other factors could lead to material differences between the act ...

Core Viewpoint - Bayer is emphasizing the significance of the U.S. Supreme Court's review regarding federal preemption under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), which has substantial implications for manufacturers, product development, and U.S. farmers [1] Legal Strategy - The company is pursuing a class settlement to address the majority of current and future Roundup-related cases while simultaneously seeking a favorable ruling from the U.S. Supreme Court to cover cases outside the settlement [2][4] - Bayer's proposed class settlement aims to resolve the bulk of Non-Hodgkin Lymphoma claims linked to Roundup exposure before February 17, 2026, with a duration of up to 21 years [7][9] Financial Impact - Bayer has increased its litigation provisions to €11.8 billion, with approximately €9.6 billion allocated for glyphosate-related matters and €1.9 billion for PCB-related issues [6][19] - The company anticipates around €5 billion in litigation cash outflows in 2026, which will lead to negative free cash flow for that year [6][16] Settlement Details - The class settlement is structured as a long-term compensation program, negotiated with multiple plaintiff law firms, and requires nearly 100% participation to avoid termination [8][13] - Payments under the settlement will be tiered and capped, designed to decline over time based on exposure type and age at diagnosis [9][10] Financing Strategy - To finance the settlements, Bayer has secured an $8 billion loan facility and plans to utilize senior bonds and equity credit instruments, without a planned capital increase [17]

Bayer (OTCPK:BAYR.Y) Update Summary Company Overview - Bayer is involved in the glyphosate litigation, specifically related to its subsidiary, Monsanto, and has reached a class settlement agreement in the United States [1][3]. Key Points Settlement Agreement - Bayer announced a class settlement agreement to resolve current and potential future glyphosate litigation in the U.S. [3][4]. - The settlement involves capped annual payments declining over time, spread over a period of up to 21 years, pending court approval [3][4]. - The settlement aims to provide speed and containment over prolonged legal battles, allowing Bayer to focus on its core mission [3][4]. Financial Implications - Bayer increased its litigation provision from EUR 7.8 billion to EUR 11.8 billion, with approximately EUR 9.6 billion allocated for glyphosate-related claims [10][36]. - The company expects litigation-related cash outflows to total around EUR 5 billion in 2026, leading to negative free cash flow for that year [11][12]. - Annual payments for litigation-related costs are anticipated to be around EUR 1 billion for the next five years, decreasing significantly thereafter [11][12]. Supreme Court Case - The Supreme Court is set to review Bayer's case, which could provide clarity on federal preemption regarding glyphosate claims [5][17]. - A favorable ruling could address cases not covered by the settlement and disincentivize opt-outs from the settlement [5][17][64]. Regulatory Clarity - Bayer emphasizes the need for regulatory clarity on crop protection products, which is critical for U.S. farmers and the agricultural industry [6][13]. - The company is preparing to launch a new herbicide, Icafolin, and seeks to ensure that American farmers have access to essential agricultural products [6][13]. Class Settlement Details - The settlement covers current and potential future plaintiffs exposed to Roundup before February 17, 2026, with a long-term claims program lasting up to 21 years [19][20]. - The settlement is supported by leading plaintiff law firms, indicating a fair arrangement for plaintiffs [19][20]. - A robust notice process will inform class members about their rights regarding the settlement [20][21]. Future Strategy - Bayer aims to refocus on its mission of "Health for All, Hunger for None" and is committed to advancing its pharmaceuticals and agricultural products [24][23]. - The company is undergoing a transformation to enhance operational efficiency and strategic flexibility [56][57]. Additional Considerations - The settlement is expected to impact employee jobs and divert funding from new product development towards litigation costs [14]. - Bayer maintains objections to the current tort system, which necessitates such settlements [14]. Conclusion - Bayer's recent settlement agreement represents a significant step towards resolving ongoing litigation and refocusing on its core business objectives. The financial implications and the upcoming Supreme Court ruling will be critical in shaping the company's future strategy and operational focus.

Bayer Update Summary Company Overview - **Company**: Bayer (OTCPK:BAYR.Y) - **Date of Briefing**: February 17, 2026 Key Points Legal Settlements and Litigation - Bayer has reached a settlement agreement regarding glyphosate-related litigation, which is currently pending court approval in Missouri. This agreement is crucial as it addresses a significant number of current and future claims related to Non-Hodgkin Lymphoma (NHL) allegedly caused by Roundup exposure [1][10][12] - The settlement is designed to provide closure for the Roundup litigation and is supported by several leading plaintiff law firms, indicating a fair arrangement for plaintiffs [13][14] - The company has increased its litigation provision from EUR 7.8 billion to EUR 11.8 billion, with approximately EUR 9.6 billion allocated for glyphosate-related claims and EUR 1.9 billion for PCB-related claims [5][27] - Bayer anticipates litigation-related cash outflows of approximately EUR 5 billion in 2026, leading to negative free cash flow for that year [6][28] Supreme Court Involvement - The Supreme Court's decision on the Durnell case is critical as it could impact claims not covered by the settlement and provide clarity on federal preemption regarding crop protection products [2][11] - A favorable ruling could disincentivize opt-outs from the settlement and provide essential regulatory clarity for U.S. farmers [2][11] Financial Implications - Bayer plans to finance the settlement through a secured bank loan facility of $8 billion and will not utilize previously authorized capital increases [7][28] - The company expects annual litigation-related payments to stabilize at approximately EUR 1 billion for five years following 2026, after which payments will significantly decrease [6][28] Future Outlook - Bayer is committed to its mission of "health for all, hunger for none" and aims to focus on its pharmaceutical pipeline and agricultural innovations [18] - The company is preparing to launch new products, including a new herbicide, Icafolin, in Brazil, highlighting the urgency for regulatory clarity in the U.S. [3][8] Additional Considerations - The settlement process includes a robust notice system for class members, allowing them to opt-out if desired. Bayer retains the right to terminate the settlement if opt-outs exceed a certain threshold [15][16] - The settlement is structured to address both current and future claims, reflecting the long latency of NHL, and will run for up to 21 years [14][16] Strategic Focus - Bayer is undergoing a transformation to enhance its operational efficiency and is focused on maintaining a solid investment grade while managing its debt levels [49][75] - The company emphasizes the importance of being the best home for its various business segments, including pharmaceuticals and crop science [48][49] Conclusion - Bayer's recent developments in litigation settlements and strategic focus on innovation and regulatory clarity are pivotal for its future growth and operational stability. The outcomes of the Supreme Court case and the acceptance of the settlement will significantly influence the company's trajectory in the coming years [1][2][18]

Core Insights - Bayer AG reported third-quarter 2025 core earnings of 17 cents per American Depositary Receipt (ADR), exceeding the Zacks Consensus Estimate of 13 cents per ADR, and up from 7 cents per ADR in the same quarter last year [1] - Core earnings per share surged 137.5% year over year, primarily driven by the Crop Science Division's performance [1][8] - Total sales for the quarter were $11.289 billion (€9.7 billion), reflecting a 3.1% decline on a reported basis, with volume growth of 5% offset by a negative pricing impact of 4.1% and a 4.5% negative currency impact [2] Crop Science Division - Crop Science sales increased by 1.3% to €3.8 billion, supported by strong growth in Corn Seed & Traits and non-glyphosate-based herbicides [5] - Corn Seed & Traits sales surged 22.4%, driven by higher planted areas in North America and a solid start to the season in Latin America [5] - Non-glyphosate herbicides sales rose 2.8%, while glyphosate-based product sales remained flat year over year [5] - Fungicide sales decreased by 6.3% due to dry weather conditions in the Europe/Middle East/Africa region [6] Pharmaceuticals Division - Revenues in the Pharmaceuticals segment increased by 0.4% to €4.33 billion [10] - Sales of the ophthalmology drug Eylea decreased by 11.2% to €731 million, impacted by lower prices and competitive pressure from generics [10] - The launch of Eylea 8 mg helped offset some declines, accounting for approximately 27% of overall Eylea sales [11] - Sales of oral anticoagulant Xarelto fell by 31.4% to €540 million due to competitive pressures [13] - Nubeqa sales surged 56.2% to €622 million, and Kerendia sales increased by 85.4% [14] Consumer Health Division - Consumer Health sales rose by 2% to €1.4 billion, although growth was hindered by challenging market conditions in North America and Asia-Pacific [15] - Nutritionals sales increased by 1.1%, while Allergy & Cold business declined by 7.8% [15] Guidance and Pipeline Updates - Bayer reaffirmed its 2025 sales guidance of €46-€48 billion [8][16] - The company expects Consumer Health sales growth to be between -1% to +1% due to a challenging market environment [16] - Recent FDA approval of elinzanetant for menopause-related symptoms is a significant boost for the company [20] - The new drug application for gadoquatrane has been accepted for review in the U.S. and China [18] Market Performance - Year-to-date, Bayer's shares have surged by 62.2%, significantly outperforming the industry gain of 8.4% [2]

Core Insights - Bayer AG reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), exceeding the Zacks Consensus Estimate of 25 cents per ADR and up from 25 cents per ADR in the same quarter last year [1] - Core earnings of €1.23 per share increased by 30.9% year over year, attributed to lower interest expenses and reduced tax outlay [1] Financial Performance - Total sales for the quarter were $12.18 billion (€10.7 billion), a decrease of 3.6% on a reported basis, with volume growth of 0.7% and a positive pricing impact of 0.2% offset by a 4.9% negative currency impact [2] - Sales surpassed the Zacks Consensus Estimate of $12 billion, and on a currency and portfolio-adjusted basis, sales rose by 0.9% year over year [2] - Year-to-date, Bayer's shares have increased by 63.1%, contrasting with a 3.7% decline in the industry [2] Segment Performance - Bayer operates under three segments: Crop Science, Pharmaceuticals, and Consumer Health [4] - Crop Science sales grew by 2.2% to €4.8 billion, driven by a 29.5% increase in Corn Seed & Traits sales due to higher planted areas and price increases [5] - Pharmaceuticals segment sales rose by 0.6% to €4.47 billion, with notable growth from Nubeqa (up 50.5% to €546 million) and Kerendia (up 67.1%) [10] - Consumer Health sales increased slightly by 0.2% to €1.4 billion, with mixed performance across subcategories [13] Guidance and Future Outlook - Bayer raised its 2025 revenue forecast to €46-48 billion, up from the previous range of €45-47 billion, due to stronger-than-expected pharmaceutical performance in the first half of the year [15] - The company expects EBITDA before special items to be between €9.7-10.2 billion in 2025, an increase from the prior projection of €9.5-10 billion [15] Pipeline Developments - Recent approvals include Eylea in China for neovascular age-related macular degeneration and Nubeqa in Europe for metastatic hormone-sensitive prostate cancer [16] - The FDA has extended the review period for elinzanetant, indicating the need for additional time for a full review [19] - Bayer is also seeking approval for the investigational contrast agent gadoquatrane in multiple regions [20] Overall Assessment - Bayer's second-quarter results exceeded expectations, with key drug approvals likely to enhance pharmaceutical sales and mitigate declines in Xarelto sales [21] - The Crop Science segment showed improvement after previous pressures, indicating a potential recovery [21]